Skip to main content
Hematological MalignancyCancer

What this study is

Acute myeloid leukemia (AML) accounts for more than 40% of leukemia mortality in the United States. Each year around ten thousand people die from the disease, most within a few years of diagnosis. Despite advances in our understanding of the disease, few improvements in the therapy of AML have been made. Collecting specimens from the blood and bone marrow will increase understanding of the effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors on human AML-SCP to develop individualized therapies. We also found DPP4 is highly expressed in other hematological malignancies in our mouse model, thus we would like to use human samples to investigate the role of DPP4 in hematological malignancy development and the mechanism underlying, especially to deeply understand the role of DDP4 in leukemia.

What's being tested

  • Study sample collection

    Intervention · OTHER

    Peripheral blood draws and bone marrow aspiration will be done during clinic visit and hospital stay.

Study details

Official title
Tumor Cell and DNA Detection in the Peripheral Blood of Patients With Hematological Malignancy
Sponsor
University of Missouri-Columbia
Conditions
Hematological Malignancy
Enrolling
50 people
Starts
2020-03-20
Est. completion
2027-03-20
Record
View on ClinicalTrials.gov ↗